Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q3 2020 · 10-Q
Revenue$132.66M$132.66M+44.1% vs Q3 2019 Net Income$9.28M$9.28M+381.0% vs Q3 2019 EPS Diluted$0.09$0.09+350.0% vs Q3 2019 Gross Profit$104,265,000+50.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$30,969,000+107.7% Free Cash Flowderived$28,187,000+131.1% Margins · derivedGross margin78.6%+3.5 pt vs Q3 2019
Operating margin11.3%+7.1 pt vs Q3 2019
Net margin7.0%+4.9 pt vs Q3 2019
ended Sep 30, 2020 · filed Oct 29, 2020 · 29 d after period end